Brazilian Marketing Authorisation for Swine Vaccine Circo/MycoGard^®

7 January 2021

 

BRAZILIAN MARKETING AUTHORISATION FOR SWINE VACCINE CIRCO/MYCOGARD^®

ECO Animal Health Group plc is pleased to announce that it has received a marketing authorisation from Brazil’s Ministry of Agriculture, Livestock and Food Supply for Circo/MycoGard^®, a vaccine for swine.

Circo/MycoGard^® is used for the vaccination of healthy piglets against Porcine Circovirus type 2 (“PCV2”) and Mycoplasma hyopneumoniae, two of the most common primary pig respiratory disease pathogens affecting the health and productivity of swine globally.

This marketing authorisation is the first licence obtained by ECO-Pharm Limited, a joint venture established in the Republic of Ireland in 2018 between ECO Animal Health Ltd, a wholly owned subsidiary of the Group, and Pharmgate Corp (“Pharmgate”) of Wilmington, North Carolina, USA responsible for the registration, marketing, sale and distribution of a number of Pharmgate LLC swine vaccine products.

Marc Loomes, CEO said:

“Brazil is a globally important swine market which is reaching record pork export levels. This first vaccine marketing authorisation in Brazil marks a significant milestone as we build our capability with vaccines and broaden our product portfolio. The speed with which Circo/MycoGard^® was approved in Brazil under difficult circumstances is most gratifying and a credit to the team.”

Colin Gray, President and CEO of Pharmgate commented:

“Our joint international efforts are vitally important to the long term growth of our companies. I am very pleased with our teams and the work they have accomplished in getting our first vaccine into this highly important market. I look forward to similar success over the coming months and years.”